Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

Home Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

/ Publications

Share the Post

About the Author

Related Posts

AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors
Synergistic Antitumor Activity of nab-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Baiteng Zhao, PhD

Comments

Comments are closed.